Table 3. Central retinal thickness (μm) during the 1-year follow-up study.
| Baseline | 4 Months | 8 Months | 12 Months | |
|---|---|---|---|---|
| All patients, median CMT (95% CI) | 403 (384–476) | 297 (268–321, p: <0.0001)a | 310 (272–337, p: 0.74)a | 266 (253–28, p: 0.81)a |
| PRN regimen | 346 (315–414) | 256 (249–284, p: 0.02)a | 260 (250–309, p: 0.83)a | 252 (239–265, p: 0.158)a |
| vs baseline 0.045 | vs baseline 0.002 | |||
| Fixed regimen group (loading phase+2q8) | 480 (397–539) | 321 (297–380, p: <0.0001)a | 333 (308–386, p: 0.49)a | 332 (310–375, p: 0.56)a |
| vs baseline <0.001 | vs baseline <0.001 | |||
| PRN group vs fixed regimen group | (p: <0.0001) | (p: 0.01) | (p: 0.02) | (P<0.001) |
Abbreviations: fixed regimen, loading phase+bimonthly injections; PRN, pro re nata strategy.
a
Compared with baseline value.
Statistically significant reduction in median CMT was recorded in both subgroups at the 4-month visit. Afterwards, stabilization in median CMT values was maintained until the end of the 1-year follow-up study in both groups.